cannabis market research
Linkedin

Intelligence · M&A & Funding

Every cannabis deal — and the companies behind them.

The M&A & Funding Tracker is the most complete record of cannabis transactions anywhere: who bought what, for how much, on what terms. Free with your email.
Get free access →
See what’s inside ↓
Live
550+
deals and counting
Updated continuously
550+
deals tracked
$40bn+
disclosed value
20+
countries covered
2017–today
full deal history
The problem

You can find most cannabis deals. You just can't reliably compare them.

Cannabis deal news is everywhere; comparable deal data is not. So the simple questions stay unanswerable. Five things stop news from being usable data — here's how the Cannamonitor Deal Tracker fixes each.

Each problem, and the fix. Tap to expand ↓

Problem 1Deals are unclassified
Cannamonitor Deal Tracker — pre-classified

Every deal is tagged by vertical, country, type and stage, so the whole market is filterable instead of a pile of headlines. Pull "all medical-cannabis M&A in Germany since 2023" in seconds.

Every deal tagged
Problem 2Currencies don't match
Cannamonitor Deal Tracker — USD-normalised

Every figure is converted to USD at a stated FX basis, so a German raise and a US acquisition compare like-for-like.

12 currencies normalised
Problem 3The headline isn't the price
Cannamonitor Deal Tracker — consideration split

Upfront, earn-out and equity broken out, so you see what was actually paid — not the press-release number.

·· % of deals carry earn-outs
Problem 4Deal stage is ambiguous
Cannamonitor Deal Tracker — explicit stage

Each deal is tracked LOI → signed → closed, with no double-counting of the same transaction across announcements.

Problem 5Sources are scattered or paywalled
Cannamonitor Deal Tracker — source-linked

Every entry links to its original filing, release or regulatory document — open, verifiable and citable.

550+ source links

Free — what your email unlocks

The full tracker. Every deal. No paywall on the data.

Every deal in the tracker — 550+ and counting. Filter by country, vertical, deal type and stage. Every entry normalised to USD and linked to its original source. No paywall on the deal record itself.
A sample of records from the trackerSnapshot 23 Jun 2026 · click a header to sort
Date ↕Deal ↕Country ↕Vertical ↕Type ↕Company intelligence (Decide)
2026Curaleaf → Northern Green CanadaCanadaMedicalAcquisition███🔓 Get free access →
2025Tilray → craft beverage portfolioUnited StatesAdjacentAcquisition███🔓 Get free access →
2025Sanity Group — Series CGermanyMedicalEquity raise███🔓 Get free access →
2024SNDL → Nova Cannabis (majority)CanadaRecreationalAcquisition███🔓 Get free access →
2023Tilray → HEXOCanadaRecreationalAcquisition███🔓 Get free access →
2023Curaleaf → Four20 PharmaGermanyMedicalAcquisition███🔓 Get free access →
2022Cresco Labs → Columbia CareUnited StatesMedicalMerger███🔓 Get free access →
2021Trulieve → Harvest HealthUnited StatesMedicalAcquisition███🔓 Get free access →
2021Jazz → GW PharmaceuticalsUnited KingdomPharmaAcquisition███🔓 Get free access →
2018Constellation → Canopy GrowthCanadaRecreationalEquity raise███🔓 Get free access →
Get free access →

What the data shows

Nine years of cannabis dealmaking, on one schema.

Aggregate views from the live tracker · snapshot 23 Jun 2026. Exact counts behind the rounded 550+ headline.
Deals per year
2026 shown year-to-date (gold).
Deal-type mix
Coverage by vertical
Verticals overlap — figures are deals tagged, not a share of 100%.
Coverage by target market
Top 10 · full coverage spans 20+ countries.
Free — email access
Get the full tracker. Free.

All 550+ deals, every field, filters and source links — normalised to USD and source-linked. Just your email. No credit card.

Paste your HubSpot form ID to activate live capture.

Methodology · the trust layer

How we build it.

Every record follows the same rules — no exceptions.

One record, tracked over time

Each deal is a living record, not a one-off headline. We follow it across its lifecycle — rumour → LOI → signed → closed (or collapsed) — and keep the history back to 2017, so you see how terms, parties and valuations actually evolved.

Financially sense-checked

Every figure is normalised to USD at a stated FX basis and pressure-tested for coherence: upfront vs earn-out vs equity split out, multiples computed consistently, outliers queried against filings. Disclosed only — never estimated silently

Authoritative sources, cross-validated

Built only from high-quality, authoritative open sources — regulatory filings, exchange disclosures, official releases — with every material fact corroborated across multiple independent sources before it's logged. Each entry links back to the original.

Analyst-curated nuance

Humans add the judgment a scraper can't: cannabis relevance judged at the asset level (a cannabis operator buying a drinks brand is logged as non-cannabis), deal types disambiguated, edge cases reasoned. Nothing enters without review.

Largest deals by disclosed value

The deals that shaped the industry.

Parties, value, type and date are open. EV/EBITDA multiples and source briefs unlock with Decide.

Objections

Common questions.

If you have others, get in touch →
Get free access →

Yes — your email unlocks every deal, filter and source link. No card, no trial clock.

Paid tiers only add ongoing monitoring (Essentials) and company depth (Decide).

 The live tracker updates continuously (page stamped 23 Jun 2026); inside Decide it’s real-time.

The deal record should be a commodity. We earn when you need ongoing monitoring (Essentials) or the company graph behind each deal (Decide).

 Every figure links to its source. Undisclosed values are logged as undisclosed, never guessed.

Parties, date, type, stage, consideration split, country, vertical and the source link — every deal on the same fields.

A few — but all limited in different ways.

One type is much shallower on depth, scope, classification and rigour, often built by PR companies, not market-intelligence firms.

The other has strong coverage of US/Canadian debt and equity markets, but missing across Europe, Asia-Pacific and LatAm.

We’re the global, analyst-built option.

A model summarises news; it can’t hand you 550+ deals on one currency basis with the source filing attached. This is a database, not a guess.

News says a deal happened. We tell you the consideration, structure and multiple — and how it compares to every other deal.

Go deeper

Got the deals. Here’s what staying — and going deeper — buys.

AcquisitionFeb 2021
Jazz Pharmaceuticals → GW Pharmaceuticals
$7.2bn
EV / EBITDA multiple12.4x
Source briefSEC 8-K
🔓 Get free access →
MergerDec 2020
Tilray ← Aphria (reverse merger)
$3.9bn
EV / EBITDA multiple12.4x
Source briefSEC 8-K
🔓 Get free access →
Equity raiseAug 2018
Constellation Brands → Canopy Growth (38%)
~$3.5bn
EV / EBITDA multiple12.4x
Source briefSEC 8-K
🔓 Get free access →
AcquisitionMay 2021
Trulieve → Harvest Health
$2.1bn
EV / EBITDA multiple12.4x
Source briefSEC 8-K
🔓 Get free access →
MergerMar 2022
Cresco Labs → Columbia Care
$2.0bn
EV / EBITDA multiple12.4x
Source briefSEC 8-K
🔓 Get free access →
You’ve seen the free value. Essentials keeps you current; Decide turns each deal into a doorway to the company behind it.
Stay current · Essentials
Keep up with what the deals mean.

Got the deals — now stay on top of them. Essentials adds an ongoing news stream, a monthly recap of M&A deals across 30+ markets, and insight deep-dives on the specific deals that matter.

~€14.2/mo · indicative
Go deep · Decide (paid)
Inside Decide: the company-intelligence layer behind every deal.

The tracker shows transactions. Decide connects each deal to the company behind it — so you can underwrite what the deal actually means:

  • Earnings & financials — revenue, EBITDA and margins over time
  • Company news — every development, matched to the company
  • Clinical trials — pipeline, matched by company
  • Landscape deep dives — how the deal reshapes the map
€142/month or €1,420/year
See it on a real deal:
Sample deal
Jazz Pharmaceuticals → GW Pharmaceuticals
Open this deal in Decide and 5 connected modules unlock ↓
$7.2bn
Acquisition · 2021
→ Company profile 🔓 Included in Decide (paid)
United Kingdom Pharmaceutical cannabis R&D · Manufacturer Founded1998 Key peopleJustin Gover, CEO ProductsEpidiolex · Sativex
→ Earnings & financials 🔓 Included in Decide (paid)
Revenue (quarterly)$153.6m EBITDA$44.1m Gross margin88% Net cash$481m EV/EBITDA16.3×
→ Company news 🔓 Included in Decide (paid)
Regulation Epidiolex secures expanded EU label across new epilepsy indication 12 Jun
Market Jazz reports cannabinoid-segment growth in latest quarter 28 May
Science New real-world data on CBD in treatment-resistant seizures 09 May
Every item tagged by country · company · vertical · stakeholder
→ Clinical trials 🔓 Included in Decide (paid)
Phase III Epilepsy · Dravet / LGS CBD (Epidiolex) RCT · placebo-controlled Sample sizen=120 Primary endpointseizure freq. RegistryNCT02224560
→ Landscape deep dive 🔓 Included in Decide (paid)
Competitive map Market-share shift Multiple vs comparables Analyst take

The acquisition consolidates GW's cannabinoid IP under Jazz, resetting the competitive set for prescription cannabinoid medicines across epilepsy and adjacent CNS indications, and re-rating peer multiples as strategic buyers reassess the pipeline.

Compare plans

Free vs Essentials vs Decide.

Free
email		EssentialsDecide
paid
Full M&A tracker (all deals, filters, source links)✓✓✓
News stream—✓✓
Monthly M&A recap (30+ markets)—✓✓
Insight deep-dives on specific deals—✓✓
Company profiles——✓
Earnings database——✓
Company news matched by company——✓
Clinical trials matched by company——✓
Landscape deep dives——✓
EV / EBITDA multiples——✓
PriceFree~€14.2/mo
indicative		€142/mo
or €1,420/yr

Start free.
Stay current with Essentials.
Go deep with Decide.

The deal data is always free. Essentials keeps you current; Decide adds the company-intelligence layer.
Get free access →
Compare plans →